by In Lam  , Irina Gutman  , Ashley Feist  and Mark Mariski

Received: 10 March 2017;  Published: 22 June 2017;  doi: 10.21926/obm.transplant.1701003

After lung transplant, infection is a leading contributor to morbidity and mortality, and hypogammaglobulinemia (HGG) may be an important risk factor for many of these infections.  Some reports suggest that HGG not only increases the risk of various infections, but also worsens survival.  The incidence of HGG has been shown to increase after lung transplant, and may be as high as 70%.  In order to mitigate this risk, intravenous immunoglobulin G (IVIG) replacement for the treatment of HGG has be [...]

by Gerald P. Morris

Received: 22 February 2019;  Published: 11 April 2017;  doi: 10.21926/obm.transplant.1701002

(1) Background: Lung transplantation is an increasingly utilized treatment for end-stage lung disease. Scarcity of organ donors limiting transplantation underscores the importance of optimal histocompatibility testing approaches to facilitate organ allocation and avoid immunologic rejection. Significant data has emerged over the past decade to define the role of alloantibodies against HLA in the pathogenesis of post-lung transplant complications. (2) Methods: Medical literature from 1996–2016 re [...]

by Pål Dag Line

Received: 07 April 2017;  Published: 11 April 2017;  doi: 10.21926/obm.transplant.1701001